{"filing":{"accession_number":"0001193125-26-269567","cik":"0001768446","ticker":"CLYM","company_name":"Climb Bio, Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"d92589d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526269567/d92589d8k.htm"},"events":[{"id":10306,"run_id":9040,"accession_number":"0001193125-26-269567","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Climb Bio entered into an Open Market Sale Agreement with Jefferies on June 12, 2026, authorizing the sale of up to $100 million in common stock through an at-the-market offering under Rule 415(a)(4), representing a registered dilutive equity issuance that materially affects shareholder ownership and capital structure.","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":6592,"accession_number":"0001193125-26-269567","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Climb Bio entered into an Open Market Sale Agreement with Jefferies on June 12, 2026, authorizing the sale of up to $100 million in common stock through an at-the-market offering under Rule 415(a)(4). This is a registered dilutive equity issuance that would materially affect shareholder ownership and the company's capital structure, making it material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:02:01.535530+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":10307,"run_id":9040,"accession_number":"0001193125-26-269567","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The Company terminated its $22.35 million Equity Distribution Agreement with Oppenheimer \u0026 Co. effective June 11, 2026, without incurring penalties and without having sold any shares under the agreement, eliminating a previously-available financing option and signaling a change in the Company's capital strategy.","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":6593,"accession_number":"0001193125-26-269567","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The Company terminated its $22.35 million Equity Distribution Agreement (ATM offering) with Oppenheimer \u0026 Co. effective June 11, 2026, without incurring penalties and without having sold any shares under the agreement. While termination of an ATM facility is a material corporate action affecting the Company's capital-raising capacity, it does not fit neatly into the more specific event categories (not a dilutive issuance, since no shares were actually sold; not M\u0026A activity; not a routine administrative matter). The disclosure is material because it eliminates a previously-available financing option and signals a change in the Company's capital strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:02:01.535530+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6592,"accession_number":"0001193125-26-269567","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Climb Bio entered into an Open Market Sale Agreement with Jefferies on June 12, 2026, authorizing the sale of up to $100 million in common stock through an at-the-market offering under Rule 415(a)(4). This is a registered dilutive equity issuance that would materially affect shareholder ownership and the company's capital structure, making it material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:02:01.535530+00:00","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-06-12"},{"id":6593,"accession_number":"0001193125-26-269567","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The Company terminated its $22.35 million Equity Distribution Agreement (ATM offering) with Oppenheimer \u0026 Co. effective June 11, 2026, without incurring penalties and without having sold any shares under the agreement. While termination of an ATM facility is a material corporate action affecting the Company's capital-raising capacity, it does not fit neatly into the more specific event categories (not a dilutive issuance, since no shares were actually sold; not M\u0026A activity; not a routine administrative matter). The disclosure is material because it eliminates a previously-available financing option and signals a change in the Company's capital strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:02:01.535530+00:00","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-06-12"}]}